started · updated
Sunshine Holdings reports significant profit and revenue growth
Sri Lankan conglomerate Sunshine Holdings PLC reported strong financial results for the period ending September 30, 2026. For the September quarter, net profit attributable to equity holders rose 80.3 percent to 1.45 billion rupees, while revenue increased 32 percent to 21.65 billion rupees.
The company’s diversified portfolio saw growth across its healthcare, consumer, and agribusiness sectors. The consumer sector experienced the strongest expansion, driven by tea export revenue and the consolidation of Joint Agri Products Ceylon. Healthcare revenue grew 20.5 percent, though gross margins were pressured by price reductions from the National Medicines Regulatory Authority and the impact of rupee depreciation on imported products.
For the first half of the fiscal year, consolidated revenue reached 40.2 billion rupees, a 24.4 percent year-on-year increase. Profit after tax for the six-month period rose 44.3 percent to 3.7 billion rupees. Additionally, the group established an equal-share joint venture with India’s Zydus Lifesciences to manufacture oral solid dosage medicines at a new 20 million USD facility in the Horana Export Processing Zone.
Entities
National Medicines Regulatory Authority · Shyam Sathasivam · Sri Lanka · Sunshine Holdings PLC · Zydus Lifesciences